Esperion Therapeutics | ESPR - Ebitda


Esperion Therapeutics reported $-9.93M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cipla INR 9.55B 3B Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Geron USD -21.29M 11.82M Dec/2025
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Sanofi EUR 3.31B 3.65B Mar/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024